Search

Researchers at Shanghai University have developed a new method for detecting specific targets using self-assembled peptide nanoparticles coupled with SERS nanotags. This innovative approach allows for high sensitivity and specificity in detecting targets such as the liver fibrosis marker LECT2. The research, supported by the National Natural Science Foundation of China, highlights the potential for generalizing this method to efficiently detect various targets, showcasing the adaptability and versatility of the technique. [Extracted from the article]

Researchers at the Biomedical University of Rome have published a study on Non-Alcoholic Fatty Liver Disease (NAFLD), highlighting the importance of risk stratification and prognostication for optimal patient care. The study emphasizes the role of liver fibrosis as a predictor of poor outcomes and discusses the genetic and acquired factors influencing disease progression. The research also introduces promising biomarkers for assessing disease activity over time, particularly in response to therapeutic interventions. For more information, readers can refer to the Journal of Physiology and Biochemistry. [Extracted from the article]

A study conducted at University Hospital Rennes focused on screening for compensated advanced chronic liver disease (cACLD) in patients with substance use disorders. The research aimed to assess the feasibility and acceptability of using transient elastography (TE) for liver fibrosis evaluation in outpatient addiction clinics. The study found that opportunistic cACLD screening using TE in addiction clinics was feasible, with good results. This research provides valuable insights into the importance of screening for liver disease in high-risk populations. [Extracted from the article]

Researchers at the University of Hong Kong conducted a study on the effects of intermittent hypoxia (IH) on hepatic expression of fatty acid translocase CD36 in lean and diet-induced obese mice. The study found that IH may lead to liver injury through differential regulation of CD36 expression in these mice. The research was supported by the Sanming Project of Medicine in Shenzhen, China, and was published in the Biomedical Journal. For more information, readers can contact Judith Choi Wo Mak at the University of Hong Kong, Shenzhen Hospital. [Extracted from the article]

A recent study conducted at West China Hospital explored the relationship between body composition and the progression of non-alcoholic fatty liver disease (NAFLD) in patients with obesity. The research found that certain CT-based body composition indicators, such as high visceral fat index (VFI), were significantly associated with the progression of NAFLD in these patients. The study suggests that patients with specific body composition characteristics may require close monitoring and timely management to address the risk of NAFLD progression. [Extracted from the article]

Researchers at the First Affiliated Hospital of Wenzhou Medical University conducted a study on the association between liver fibrosis and in-hospital mortality in patients with sepsis-induced coagulopathy (SIC). The study, which included 948 patients diagnosed with SIC, found that higher liver fibrosis scores, particularly Fib-4 and NFS, were linked to increased in-hospital mortality. The researchers suggest that further research, especially larger prospective studies, is needed to confirm these findings. The study was published in BMC Infectious Diseases. [Extracted from the article]

A study conducted at Ahvaz Jundishapur University of Medical Sciences compared liver fibrosis in patients with diabetes and prediabetes. The research found that diabetic patients had a higher severity of liver fibrosis compared to prediabetic patients. Both groups showed a significant relationship between liver fibrosis and HbA1C levels, with prediabetes also being associated with an elevated risk of liver fibrosis. The study did not find a statistically significant relationship between liver fibrosis and age, sex, body mass index, ALT, and ALKP in either group. [Extracted from the article]

A study conducted at Putian University in Fujian, China, focused on the diagnostic value of liver biopsy in patients with acute and chronic liver diseases, particularly chronic hepatitis B. The research aimed to evaluate the efficacy of antiviral therapy through repeated liver biopsies. The study found a 79.45% concordance rate between clinical and histopathological diagnoses, with liver biopsy proving useful in assessing liver fibrosis before and after antiviral treatment for chronic hepatitis B. The findings suggest that liver biopsy plays a crucial role in diagnosing liver diseases and monitoring treatment effectiveness. [Extracted from the article]

A recent study conducted at the University Clinical Center of Serbia focused on optimizing hepatitis C treatment monitoring by assessing the sustained virological response (SVR) at 4 weeks compared to 12 weeks post-therapy. The research included 216 patients with chronic hepatitis C and found that achieving SVR at 4 weeks had a high sensitivity of 100% for most genotypes, except for genotype 1b. Younger age and less advanced liver fibrosis were identified as predictors of achieving SVR at both 4 and 12 weeks. The study suggests that shortening the monitoring period to 4 weeks could be effective for certain patient populations, potentially improving treatment outcomes and reducing loss to follow-up. [Extracted from the article]

A recent study conducted at the University of Lille Hospital explored the link between acute hepatitis and severe hypophosphatemia induced by excessive production of FGF23. The researchers found evidence of acute FGF23 liver expression in cases of acute hepatitis, leading to renal phosphate wasting. The study utilized clinical observations, histological data, and mouse models to support their findings, suggesting a potential mechanism for the development of hypophosphatemia in acute hepatitis cases. [Extracted from the article]

Researchers at the First Affiliated Hospital of Zhengzhou University conducted a study on hepatocellular carcinoma (HCC) with cirrhosis to understand the molecular mechanisms underlying its development. Using multi-omic data analysis, they identified gene networks and cell types associated with cirrhosis in HCC, highlighting the role of immune and malignant cells in stimulating fibrotic activity. The findings suggest potential therapeutic strategies for liver fibrosis. The study was published in Scientific Reports and can be accessed for further information. [Extracted from the article]

A recent study conducted at Saga University Hospital in Japan focused on the awareness and implementation rate of ultrasound elastography and attenuation imaging in liver cancer surveillance. The research found that while these technologies are crucial for detecting advanced liver fibrosis and steatosis, their availability in medical facilities in Saga Prefecture is limited. The study highlighted the need for increased awareness and utilization of ultrasound elastography and attenuation imaging, especially considering the high prevalence of steatotic liver disease. [Extracted from the article]

Researchers at the Chinese Academy of Agricultural Sciences in Shanghai, China, have found that schistosoma japonicum sja-let-7 inhibits the growth of hepatocellular carcinoma cells by regulating col1a2. This study highlights the potential therapeutic application of helminth-derived miRNAs in liver fibrosis and hepatocellular carcinoma. The findings suggest that sja-let-7 could serve as a promising therapeutic agent in the treatment of HCC. [Extracted from the article]

Researchers at Wuhan University in Hubei, China, have conducted a study on liver cirrhosis, a condition that can lead to liver failure and death. The study focused on the use of insulin-like growth factor 2 (IGF2) combined with bone marrow-derived macrophages (BMDMs) to treat mice with liver cirrhosis induced by CCl4. The research found that combining IGF2 with BMDM reduced liver inflammation and fibrosis, increased hepatocyte proliferation, and inhibited hepatic stellate cells (HSCs) activation. This study provides a theoretical basis for potential future use of BMDM-based cell therapy to treat liver cirrhosis. [Extracted from the article]

A new humanized transgenic mouse model for Alpha-1 Antitrypsin Deficiency (AATD) has been developed, utilizing a CRISPR-Cas9 generated SERPINA1-null mouse background. This model demonstrates clinically relevant manifestations of liver pathology associated with AATD, including hepatic accumulation of human Alpha-1 Antitrypsin globules, liver fibrosis, and mild systemic inflammation. The study suggests that this model could be valuable for studying Alpha-1 Antitrypsin loss of function, replicating the pathophysiology of AATD-associated liver disease, and evaluating potential therapeutic interventions. [Extracted from the article]

Researchers from Hong Kong Polytechnic University have developed a deep learning-based approach called Transformer-enhanced Hough Transform (TEHT) to detect shear wave trajectories in liver fibrosis assessment. This method outperformed other deep learning models, showing strong concordance with the gold standard in evaluating liver stiffness and velocity. The study suggests the application of the TEHT model for assessing liver fibrosis due to its superior performance. The research was supported by the Research Institute for Smart Ageing of the Hong Kong Polytechnic University and has been peer-reviewed. [Extracted from the article]

A study published in Gastroenterology Week explores the role of estrogen receptor 1 (ESR1) signaling in hepatic stellate cells and its impact on liver fibrosis. The research suggests that sex hormone depletion in female mice exacerbates liver fibrosis, while estradiol replacement in male mice can alleviate the severity of the disease. Genetic deletion of ESR1 in mouse hepatic stellate cells was found to significantly promote liver fibrosis, highlighting the importance of ESR1 signaling in the sexual dimorphism of this condition. [Extracted from the article]

A study conducted in Jiangsu, People's Republic of China, explored the relationship between the systemic inflammation response index (SIRI) and hepatic fibrosis progression and mortality outcomes in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). The study, which included 5126 patients with MASLD, found that a higher SIRI was associated with increased odds of advanced hepatic fibrosis and greater all-cause and cardiovascular mortality. The research concluded that the SIRI could be a valuable tool for identifying MASLD individuals at risk of developing advanced hepatic fibrosis and predicting mortality outcomes. [Extracted from the article]

Research conducted at the Institute of Optical Imaging & Sensing in Shenzhen, People's Republic of China, has focused on liver fibrosis, a characteristic of chronic liver diseases. The study utilized Mueller matrix imaging to develop a fiber-sensitive polarization feature parameter (PFP) for identifying fibrous structures in liver tissues. Results showed a correlation between PFP image textures and liver fibrosis tissues, offering potential for quantitative diagnostic indicators in staging liver fibrosis. The study highlights the potential of PFP imaging to streamline diagnostic processes and provide texture-based insights into liver fibrosis. [Extracted from the article]

A recent study conducted at Nagasaki Harbor Medical Center in Japan explored the effects of pemafibrate on patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The research found that pemafibrate reduced liver stiffness in patients with hyperlipidemia and MASLD, particularly in those with a Fibrosis-4 index above 1.3 or liver stiffness above 8 kPa. While there is currently no approved treatment for MASLD, pemafibrate may offer a promising option for patients with mild liver stiffness. [Extracted from the article]

A recent study conducted at Children's Hospital Philadelphia explored the relationship between spleen shear wave elastography measurements and liver fibrosis in patients with Fontan physiology. The study found that spleen stiffness values did not correlate with biopsy-determined scoring of liver fibrosis in these patients. This preliminary investigation sheds light on potential markers for Fontan-associated liver disease and highlights the need for further research in this area. The study was peer-reviewed and offers valuable insights into liver fibrosis in specific patient populations. [Extracted from the article]

Researchers at the Chinese Academy of Medical Sciences have conducted a study on liver fibrosis, a condition that plays a crucial role in liver disease progression. The study focused on the synthesis and anti-liver fibrosis research of aspartic acid derivatives, with promising results showing inhibitory effects on liver fibrosis activity. The research identified new compounds with potent anti-liver fibrosis effects, paving the way for the development of novel treatments. For more information, the full article can be accessed through the publisher, MDPI AG. [Extracted from the article]

A recent study conducted at Zhejiang University School of Medicine explored the correlation between Hashimoto's thyroiditis and Metabolic dysfunction-associated fatty liver disease (MAFLD) while screening high-risk groups for liver fibrosis in MAFLD patients. The study found that age, BMI, FBG, and AST are risk factors for high-risk liver fibrosis in MAFLD patients, with specific age and AST levels indicating increased risk. The research highlights the importance of identifying indicators for liver fibrosis in MAFLD patients to improve prevention and treatment strategies. [Extracted from the article]

A recent study conducted among community health workers in a rural area focused on the risk assessment of Metabolic Associated Steatotic Liver Disease (MASLD), commonly known as non-alcoholic fatty liver disease (NAFLD). The study found that physical inactivity was linked to fatty liver alterations and liver fibrosis, along with an elevated waist-hip ratio. The researchers emphasized the importance of lifestyle changes, such as a healthy diet and regular exercise, to prevent and manage fatty liver disease. This study provides valuable insights for healthcare providers to develop personalized interventions and promote healthy lifestyles to reduce the burden of MASLD in the community. [Extracted from the article]

Researchers from Shaanxi Provincial People's Hospital in China conducted a study on the role of hsa_circ_0072765 in liver fibrosis. They found that hsa_circ_0072765 promoted the progression of hepatic stellate cells (HSCs) treated with transforming growth factor-beta (TGF-β) by interacting with miR-197-3p and upregulating TRPV3. This research provides insights into the molecular mechanisms underlying liver fibrosis and potential therapeutic targets. The study was published in Histology and Histopathology and has been peer-reviewed. [Extracted from the article]

Researchers at Huazhong University of Science and Technology have reported new insights into the role of immunomodulatory extracellular vesicles in the pathogenesis of liver fibrosis. Liver fibrosis is a chronic disease that can progress to liver failure and hepatocellular carcinoma. Extracellular vesicles play a crucial role in mediating the inflammatory microenvironment of liver fibrosis and have potential applications in diagnosis and treatment due to their immunomodulatory properties. The study highlights the advantages of extracellular vesicle-based therapies, such as stability, biocompatibility, and low immunogenicity, for specific treatments of liver fibrosis. [Extracted from the article]

Researchers from Justus-Liebig-University in Germany conducted a study on liver fibrosis in mice infected with S. mansoni, a parasite that affects millions worldwide. The study found that younger mice with a higher egg burden experienced enhanced liver fibrosis, while older mice showed improvements in liver damage, inflammation, and fibrosis. The research highlights the importance of understanding age-dependent liver damage in patients with schistosomiasis. For more information, the full report can be accessed through Cells journal. [Extracted from the article]

Researchers at the University of Florida have reported new data on pulmonary emphysema, specifically focusing on the effects of Berberine on liver inflammation and fibrosis in a transgenic murine model. The study found that Berberine exacerbated liver inflammation and fibrosis in mice with the PiZ mutation, suggesting that it should be avoided by patients with Alpha-1 antitrypsin deficiency. The research was supported by the Alpha-1 Foundation and provides valuable insights into potential therapeutic effects and toxicities of Berberine in specific genetic contexts. [Extracted from the article]

The article discusses metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), which affect a significant portion of the global population. These conditions are closely linked to obesity, poor diet, and lack of exercise, leading to fat accumulation in the liver, inflammation, and scarring. Researchers at EPFL have found that inhibiting the enzyme ACMSD can increase NAD+ levels in the liver, reducing inflammation, DNA damage, and fibrosis in mouse models of MASLD/MASH. This discovery suggests that blocking ACMSD could be a potential new therapy for these liver diseases, highlighting the importance of metabolic pathways in liver health. [Extracted from the article]

The article discusses a clinical trial, NCT06629909, focusing on the safety and effectiveness of Human Umbilical Cord Mesenchymal Stem Cell (HUCMSC) derived secretome injection in patients with liver cirrhosis. The trial aims to evaluate the impact of secretome injection on liver fibrosis, liver function, inflammatory cytokines, quality of life, and encephalopathy. Patients will receive secretome injections or standard treatment for four months and undergo various tests to assess treatment outcomes. The study is non-randomized, with a primary completion date of October 31, 2025, and is being conducted in Indonesia. [Extracted from the article]

The article discusses a clinical trial, NCT06632444, focusing on the use of survodutide to help individuals with non-alcoholic steatohepatitis (NASH) or metabolic-associated steatohepatitis (MASH) and moderate or advanced liver fibrosis improve their liver function. The study involves two parts, with participants randomly assigned to receive either survodutide or a placebo, injected weekly under the skin. The trial aims to assess the impact of survodutide on liver function and safety over a period of up to 7 years, with regular monitoring and assessments conducted throughout the study. [Extracted from the article]

The article discusses a clinical trial, NCT06632457, focusing on the use of survodutide to help individuals with liver diseases like NASH/MASH who have cirrhosis. Participants are randomly assigned to receive either survodutide or a placebo, with the aim of improving liver function. The study involves regular injections, dietary counseling, and exercise recommendations over a period of up to 4.5 years, with health monitoring and data collection to assess the treatment's effectiveness. [Extracted from the article]

The research conducted at the St. Petersburg Pasteur Institute focuses on the role of the chemokine CX3CL1/Fractalkine in chronic viral hepatitis B. The study found that the concentration of this chemokine in the blood plasma of patients with chronic hepatitis B (CHB) is reduced compared to healthy individuals and other liver diseases. The research suggests that the decreased level of CX3CL1/Fractalkine may be a negative factor in the development of CHB, as it is involved in liver fibrosis during hepatitis B virus infection. [Extracted from the article]

A recent study conducted at North Shore University Hospital in Manhasset, New York, focused on the impact of achieving a sustained virologic response (SVR) through direct-acting antivirals for hepatitis C virus (HCV) infection on the risk of hepatocellular carcinoma (HCC). The study highlighted the ongoing debate surrounding optimal surveillance strategies for patients who have achieved SVR, particularly those with advanced fibrosis or cirrhosis. The research aimed to provide new perspectives on HCC surveillance strategies for patients who have achieved SVR from HCV, addressing existing data and controversies in the field. [Extracted from the article]

A study conducted at the Medical School of Ege University in Izmir, Turkey, focused on using transient elastography (TE) to assess liver graft fibrosis in pediatric liver transplant recipients. The research found a significant correlation between TE results and fibrosis scores, indicating the potential of TE as a noninvasive method for detecting liver damage in children post-transplant. The study concluded that abnormal TE results could prompt physicians to consider liver biopsy for further evaluation. This research was published in Clinical Transplantation and can provide valuable insights into liver transplant outcomes in pediatric patients. [Extracted from the article]

A study conducted at Binzhou Medical University in Yantai, People's Republic of China, focused on the role of monoamine oxidase B (MAO-B) in liver fibrosis. The researchers developed a fluorescence probe to detect MAO-B activity in living cells and in vivo, showing promising results in distinguishing between fibrotic and normal cells. This research may offer a potential method for early diagnosis of liver fibrosis, providing a rapid and sensitive approach for in situ in vivo imaging of MAO-B. The study was supported by various funding sources and has been peer-reviewed, offering valuable insights into liver fibrosis diagnosis. [Extracted from the article]

Researchers at Czerniakowski Hospital in Warsaw, Poland, have conducted a study on primary sclerosing cholangitis (PSC), a liver disorder characterized by bile duct strictures and dilatations. The research focuses on the etiology, prevalence, treatment options, and management strategies of PSC, highlighting the importance of a multidisciplinary approach involving various medical specialists. While liver transplantation remains the most effective treatment, new therapies such as immune modulators and anti-fibrotic agents show promise but require further research for better patient outcomes. [Extracted from the article]

A recent study conducted at the University of Florida highlighted the prevalence of hepatic fibrosis in young adults with type 2 diabetes mellitus (T2D) and obesity. The research found that individuals with both T2D and obesity had a significantly higher risk of hepatic fibrosis compared to older adults. The study emphasizes the importance of screening young adults with cardiometabolic risk factors for early detection and intervention to address this health concern. [Extracted from the article]

Researchers at the University of Pittsburgh have discovered that inhibiting the heme-thiolate monooxygenase CYP1B1 can prevent hepatic stellate cell activation and liver fibrosis by accumulating trehalose. This finding suggests potential therapeutic strategies for liver fibrosis, particularly in males. The study highlights the role of CYP1B1 in liver fibrosis and the potential benefits of trehalose or its derivative lactotrehalose in treating the condition. [Extracted from the article]

Researchers from the University of Sao Paulo have conducted a study on purinergic signaling in liver diseases, focusing on calcium signaling and inflammation induction. The study highlights the role of purinergic receptors, specifically P2X and P2Y receptors, in regulating liver functionality and pathophysiology. The research suggests that pharmacological modulation of P1 and P2 receptors and downstream calcium signaling could lead to novel therapeutic approaches for liver diseases. [Extracted from the article]

The article discusses a newly launched clinical trial, NCT06626074, focusing on non-invasive biomarkers for diagnosing nonalcoholic steatohepatitis (NASH) in patients with fatty liver disease. NASH is a severe form of the disease that can lead to liver complications, and currently, diagnosis relies on invasive liver biopsies. The trial aims to evaluate the diagnostic performance of new MRI biomarkers for NASH diagnosis without the need for a biopsy. The study is being conducted at University Hospital, Angers, and is not yet recruiting participants, with a completion date set for December 1, 2026. [Extracted from the article]

Researchers from Firat University School of Medicine conducted a study comparing liver stiffness and steatosis measurements using iLivTouch and FibroScan devices on 237 adult patients with chronic hepatitis. The study found that iLivTouch had slightly higher accuracy in detecting significant fibrosis compared to other noninvasive methods. The researchers concluded that larger clinical trials are needed to further support these findings. The study was published in The Turkish Journal of Gastroenterology. [Extracted from the article]

A study conducted at Hangzhou Normal University in Zhejiang, China, focused on differentiating between idiopathic portal hypertension (IPH) and cirrhosis, two conditions often misdiagnosed due to similar symptoms. The research analyzed imaging, pathological, and serological features of 14 IPH patients and 30 cirrhosis patients, highlighting differences in liver function, spleen morphology, and portal vein abnormalities. Findings suggest that IPH is characterized by normal liver function, hypersplenism, and specific imaging features like focal nodular hyperplasia-like lesions, while cirrhosis is associated with regenerative nodules and pseudolobule formation. The study emphasizes the importance of accurate diagnosis to guide appropriate treatment measures for each condition. [Extracted from the article]

Researchers from University Hospital Schleswig Holstein in Kiel, Germany, conducted a study on Fontan patients to evaluate liver hemodynamics using 4D PC flow MRI. The study aimed to understand Fontan-associated liver disease (FALD) and its relation to abnormal flow dynamics. The research concluded that 4D PC flow MRI is a suitable tool to assess liver hemodynamics in Fontan patients, potentially aiding in the understanding and management of FALD. The study was financially supported by the charity organization "Kinderherzen wollen leben e.V." [Extracted from the article]

A recent study published in the Journal of Clinical Medicine explores the correlation between metabolic syndrome and various pathologies, including cardiovascular diseases, diabetes, and renal failure. The research emphasizes the importance of a holistic approach to managing metabolic syndrome and highlights the significance of non-invasive diagnostic tools for assessing liver fibrosis and steatosis. The findings suggest that non-invasive assessments of hepatic fibrosis and steatosis could serve as markers for disease severity and progression, particularly in patients with metabolic syndrome. [Extracted from the article]

A study conducted by researchers at Ningbo University in Zhejiang, China, explored the relationship between the atherogenic index of plasma (AIP) and metabolic dysfunction-associated fatty liver disease (MAFLD) in American adults. The study, which included data from 4473 participants, found a positive association between AIP and MAFLD, regardless of sex or diabetes status. However, no significant relationship was observed between AIP and significant liver fibrosis or cirrhosis. The findings suggest that AIP may serve as a predictor for MAFLD in the population studied. [Extracted from the article]

Researchers at the University of Health Sciences Antalya Training and Research Hospital conducted a study on Type 2 Diabetes patients to determine the rates of ultrasound examination for diagnosing metabolic dysfunction-associated fatty liver disease (MAFLD). The study included 6283 patients across 17 internal medicine clinics in Turkiye, with 27.6% of patients undergoing ultrasound examinations, revealing MAFLD in 69.9% of cases. The research highlighted a lack of awareness among clinicians regarding MAFLD and the risk of advanced fibrosis in Type 2 Diabetes patients. [Extracted from the article]

A recent study conducted at Children's Hospital of Los Angeles focused on liver diseases and conditions, specifically metabolic dysfunction-associated steatotic liver disease (MASLD) in children. The researchers compared two noninvasive imaging modalities, magnetic resonance elastography (MRE) and transient elastography (TE), to liver biopsy in order to assess their accuracy in detecting high-grade fibrosis. The study found that both MRE and TE were not accurate predictors of high-grade fibrosis, but MRE had a slightly superior area under the receiver operating characteristic curve (AUROC) compared to TE. The researchers concluded that larger studies are needed to validate these findings. [Extracted from the article]

A recent report from the University of Padova in Italy highlights the potential health benefits of tyrosol and oleocanthal, two compounds found in extra virgin olive oil (EVOO). The study suggests that these compounds may have hepatoprotective properties and could potentially mitigate chronic liver diseases and their progression to liver cancer. The research explores the mechanisms of action of tyrosol and oleocanthal, which are believed to regulate cellular pathways involved in antioxidant response, lipid metabolism, transcription factor activity, and NF-kB signaling. Understanding these mechanisms could inform the development of therapeutic agents for chronic liver diseases. [Extracted from the article]